详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Efficacy and Safety of Sorafenib as Adjuvant and Latter Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma

57| 认领 | 链接全文 |

文献详情

编号/登记号：

研究结束时间：

项目类型：

本院角色：

多中心研究：

招募状态：

试验分期：

研究类型：

研究参与人：

研究单位： [1]Southwest Hospital, China [2]Chengdu PLA General Hospital [3]Sichuan Provincial People's Hospital [4]Sichuan Cancer Hospital and Research Institute [5]Hunan Cancer Hospital [6]Cancer Hospital of Guangxi Medical University [7]The First People's Hospital of Yunnan [8]Yunnan Cancer Hospital [9]Xiangya Hospital of Central South University [10]Xinqiao Hospital of Chongqing [11]The Second Affiliated Hospital of Chongqing Medical University [12]Henan Cancer Hospital [13]First Affiliated Hospital of Chongqing Medical University [14]First Affiliated Hospital of Guangxi Medical University

研究目的：

Radiofrequency ablation is a popular treatment for recurrent hepatocellular carcinoma (HCC),but still has a higher recurrence. Sorafenib as neo-adjuvant therapy in combination of RFA was not reported yet. There's a theoretical advantage of this combination. Hence in this study the efficacy and safety of pre-administrative Sorafenib and Latter radiofrequency ablation (RFA) in Recurrent HCC will be tested in a multicenter prospective cohort study.

资源点击量：43389 今日访问量：0 总访问量：3120 更新日期：2024-09-01 建议使用谷歌、火狐浏览器 常见问题